ImmunoGen's Mirvetuximab soravtansine rules out advanced-stage study; stocks down 43% before marketing – Seeking Alpha

by



[ad_1]

  1. ImmunoGen's Mirvetuximab soravtansine rules out advanced-stage study; shares down 43% before marketing
  2. ImmunoGen Announces First Line Results of the Phase 3 FORWARD I Study on Mirvetuximab Soravtansine in the Treatment of Ovarian Cancer
  3. View full coverage on Google News

[ad_2]

Source link